Injectable testosterone ester

Testosterone Cypionate

Testosterone cypionate is an oil-soluble injectable testosterone ester. US labels state a half-life of approximately eight days after intramuscular injection, and the app uses 192 hours (8 days).

Strong evidenceGet the app

Level after one dose

Testosterone Cypionate after one dose: 50% at ~8 days, 25% at 16 days, 12.5% at 24 days.

Drawn from the half-life in the app's model, ~8 days. The model's figures

1

How Milligram users log it

Track your protocol with Milligram.

13%The 4th most tracked compound in Milligram: of people who track compounds in Milligram logged Testosterone Cypionate in the last 90 days.

Schedule

  1. Daily20%
  2. Every other day32%
  3. Twice a week35%
  4. Weekly12%
  5. Less often2%
Among people with three or more logged doses, by the average gap between their doses.

Logged doses

Half of people logged between 50 and 200 mg per dose; the median was 100 mg.

Each person's usual logged amount. The bar starts at zero; the shaded part is the middle half, the mark the median.

Tracked alongside

The share of people logging Testosterone Cypionate who also logged each.

From dose logs in the Milligram app, 90 days to 15 November 2026. Aggregated and anonymous. This describes what people recorded, not what anyone should take.

Testosterone cypionate is the oil-soluble 17 (beta)-cyclopentylpropionate ester of the androgenic hormone testosterone, as the US Depo-Testosterone label describes it.1

The Depo-Testosterone label states that it is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone.1 The same label states that safety and efficacy in men with “age-related hypogonadism” have not been established.1 The Azmiro label (revised July 2025) carries the same indication.2

The Depo-Testosterone label also states that the drug has not been shown to be safe and effective for the enhancement of athletic performance.1

The “Strong evidence” tag is also the app's own grade, and none of the sources cited here grades evidence. The Depo-Testosterone label states that “Long term clinical safety trials have not been conducted to assess the cardiovascular outcomes of testosterone replacement therapy in men”.1

The Depo-Testosterone label states that testosterone esters are less polar than free testosterone and that testosterone esters in oil injected intramuscularly are absorbed slowly from the lipid phase.1 The label states that during exogenous administration of androgens, endogenous testosterone release is inhibited through feedback inhibition of pituitary luteinizing hormone (LH), and that at large doses spermatogenesis may also be suppressed through feedback inhibition of pituitary follicle stimulating hormone (FSH).1 Bi and colleagues wrote in 2018 that intramuscular testosterone cypionate “is also likely to have flip-flop kinetics”, in which diffusion and release from the oily depot is the rate-limiting step to systemic availability.3

4

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~8 days
Bioavailability
95%
Typical dose
150–500 mg/week
Route
IM / SubQ
Time to peak
~48 h

The US labels for testosterone cypionate state that its half-life when injected intramuscularly is approximately eight days.1,2,4 The Milligram app uses a half-life of 192 hours (8 days), which matches the labels, and a time to peak of about 48 hours. No cited source reports a median or mean time to peak of about 48 hours: Nankin's testosterone peaks fell on days 2 to 5 (free testosterone days 2 to 3),5 and the Azmiro label reports a median time to peak of baseline-corrected testosterone of 71.7 hours (range 24.0 to 191.0) after a single 200 mg intramuscular dose in a prefilled syringe in 26 hypogonadal men.2 The population-model half-lives below are for total testosterone in healthy men given 100, 250 or 500 mg per week; the authors say the 250 and 500 mg regimens resemble doses illegally used by athletes.3

Table 4.1Half-life and pharmacokinetics3 rows
MeasureFigureSource and note
Half-life of total testosterone, population model4.05 days (median)Median post hoc value, 31 healthy men, 100, 250 or 500 mg per week for 14 weeks; 6.87 days with the men's own production set to zero.3
Peak after 200 mg, Nankin 1987Days 2 to 5Testosterone peak values in 11 hypogonadal men (free testosterone days 2 to 3); basal by days 13 to 14.5
Bioavailability95%The app's figure; none of the cited sources gives a bioavailability percentage for testosterone cypionate.

Level curve between doses

The chart below draws a one-compartment model with the app's half-life of 192 hours and time to peak of about 48 hours; it is an illustration and not a measured or predicted level for any person. The intervals follow the sources: weekly in McFarland and colleagues, every 2 weeks in Rivero and colleagues, and every 28 days as the upper end of the label range of two to four weeks.6,7,1

Level over 6 weeks

Interval between doses

Level, as a share of the peak after one 100 mg dose

As studied: every 7 days6, every 14 days7, every 28 days1. As logged in Milligram: the share of people with three or more logged doses on each schedule (How Milligram users log it).

An illustration from a pharmacokinetic model using a half-life of 192 hours (8 days). It is not a measured level or a suggested dose.

5

What testosterone cypionate products contain per mL

The US Depo-Testosterone label lists two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate, in a cottonseed oil and benzyl benzoate vehicle with benzyl alcohol as the preservative.1

Table 5.1What testosterone cypionate products contain per mL5 rows
ProductMakerStrengthContainerContents per mL
Depo-Testosterone1Pharmacia & Upjohn Company LLC (Pfizer)100 mg per mL10 mL multiple-dose vialCottonseed oil 736 mg, benzyl benzoate 0.1 mL, benzyl alcohol 9.45 mg
Depo-Testosterone1Pharmacia & Upjohn Company LLC (Pfizer)200 mg per mL1 mL single-dose vial and 10 mL vialCottonseed oil 470 mg, benzyl benzoate 0.3 mL, benzyl alcohol 9.45 mg
Azmiro2Azurity Pharmaceuticals, Inc.200 mg per mL1 mL single-dose vial and 1 mL single-dose prefilled syringeCottonseed oil 542 mg, benzyl benzoate 0.2 mL, benzyl alcohol 20 mg
Testosterone Cypionate Injection, USP4Sun Pharmaceutical Industries, Inc.100 mg per mL10 mL multiple-dose vialCottonseed oil 736 mg, benzyl benzoate 0.1 mL, benzyl alcohol 9.45 mg
Testosterone Cypionate Injection, USP4Sun Pharmaceutical Industries, Inc.200 mg per mL1 mL single-dose vial and 10 mL multiple-dose vialCottonseed oil 560 mg, benzyl benzoate 0.2 mL, benzyl alcohol 9.45 mg

The amounts of benzyl benzoate and cottonseed oil per mL differ between the Depo-Testosterone, Sun and Azmiro labels at the same 200 mg per mL strength.1,4,2 The Azmiro label states that injectable testosterone products “are not substitutable on a milligram-per-milligram basis”.2 The converter below only multiplies a volume by a strength in mg per mL, starting from 200 mg per mL, and does not say how much to draw or inject.1

Strength converter

US label strength: 200 mg per mL1

Arithmetic only: the amount is the volume times the strength. The vial's own label states its strength.

6

Human studies

Table 6.1Human studies8 rows
Study and yearDesignPeopleDose and lengthMain result
Nankin, 19875Hormone kinetics after usual therapeutic injections11 hypogonadal men200 mg intramuscular, biweekly injectionsTestosterone and estradiol rose threefold (testosterone peaks days 2 to 5); many men above normal days 2 to 7, basal by days 13 to 14.
Pope and colleagues, 20008Randomized, placebo-controlled crossover56 normal men aged 20 to 50Up to 600 mg/wk for 6 weeks, placebo for 6 weeksManic scores rose on the Young Mania Rating Scale (P = .002) and aggressive responses rose (P = .03); response was highly variable, with 2 of 50 men at 600 mg/wk markedly hypomanic.
Kouri and colleagues, 19969Placebo-controlled, double-blind crossover16 normal male volunteers150, 300 then 600 mg/wk, 2 weeks eachHDL cholesterol fell 21% after the first 300 mg dose and stayed down after two 600 mg doses; LDL and total cholesterol did not change; the total cholesterol/HDL-C ratio was significantly elevated during dosing and 4 weeks after the last injection, and the authors conclude the effect on cholesterol fractions persists for several weeks after discontinuation.
Bi and colleagues, 20183Randomized, double-blind; population PK/PD model31 healthy men100, 250 or 500 mg/wk for 14 weeksMedian half-life of total testosterone 4.05 days; model simulation suggests suppression of LH synthesis and spermatogenesis was more severe and of greater duration at 250 and 500 mg/wk.
McFarland and colleagues, 20176Pharmacokinetic sampling across one weekly interval11 transgender men already on weekly subcutaneous testosterone cypionate50 to 100 mg/week (median 75 mg), subcutaneousMean total and free testosterone “stable and remained well within the normal range”; no significant difference in total testosterone from 6 hours to 5 days after injection; the day 0 and day 7 pre-injection samples were 497 and 477 ng/dL (P = 0.58); mean total testosterone 627 ± 206 ng/dL across the seven between-injection samples; significant effect of time (ptime = 0.006), day 7 lower than the initial post-injection measurement (P = 0.012) and day 5 (P = 0.023); one patient (100 mg) had four values above the normal range and one (50 mg) one below; no adverse effects. supported by a Maine Medical Center grant; one author at Quest Diagnostics, no competing interest mentioned in the text read.
Choi and colleagues, 202210Versus a subcutaneous enanthate autoinjector, regression-adjusted234 hypogonadal men100 mg weekly, 12 weeksTrough testosterone rose from 313.6 to 536.4 ng/dL on intramuscular cypionate and from 246.6 to 552.8 ng/dL on the autoinjector (both p < 0.001); modality not associated with testosterone after regression (p = 0.057); lower estradiol and hematocrit with the autoinjector (both p < 0.001); no significant PSA elevation with either modality (p = 0.965).
Rivero and colleagues, 20237Randomized, open-label, 2 arms, versus intranasal gel81 randomized, 54 completed (31 intramuscular, 23 intranasal)200 mg intramuscular every 2 weeks for 4 months (gel: 11 mg three times daily)Hematocrit increased from 42.7% to 46.6% in the injection group (P < .0001) and did not change significantly on gel (P = .233).
Okano and colleagues, 202511Randomized controlled pilot, single center43 transgender men with erythrocytosis (hematocrit 50% or more) who completed100 mg intramuscular every 2 weeks for 3 months, or complete testosterone withdrawalHematocrit fell 0.8 ± 0.5% on 100 mg and 3.5 ± 0.5% with withdrawal (P < .001), a difference significant only when a reduction of more than 1.0 percentage point in hematocrit was expected; testosterone changed by 75.72 ± 123.26 ng/dL on 100 mg and -510.16 ± 120.42 ng/dL with withdrawal (P = .002); hemoglobin fell 0.97 ± 0.16 g/dL with withdrawal and 0.17 ± 0.17 g/dL on 100 mg (P = .002); within the 100 mg group diastolic blood pressure, body weight and HADS anxiety score fell (P = .040, .003, .001); no serious adverse events.

The cited summaries of Nankin, Kouri, Choi and Okano state no funder or author tie to a sponsor.5,9,10,11

Deeper analysis: the 2018 population pharmacokinetic study of weekly injections

It modelled a randomized, double-blind clinical trial that the authors describe as conducted to investigate long-term abuse effects of testosterone cypionate, in which 31 healthy men were randomized to 100 mg per week (n = 10), 250 mg per week (n = 10) or 500 mg per week (n = 11), and the model links exposure to change in LH and spermatogenesis.3 The model's median post hoc half-life of total testosterone was 4.05 days against a reported noncompartmental mean of 6.9 days, a gap the authors say “is believed to result from failure to consider endogenous testosterone production”; with endogenous secretion assumed to be 0 the median half-life rose to 6.87 days.3 The authors describe sperm count at the end of 14 weeks of dosing as “completely suppressed” in the 250 mg and 500 mg groups, while the model simulated median suppression of 98.2% and 94.9% at week 15.3 The authors give their own limitations: “The small sample size (N = 31) may limit the precise estimation of suppression level of LH and spermatogenesis” and “The study design did not follow subjects long enough to allow observation of complete recovery from inhibition of spermatogenesis”.3 The article lists the National Institute on Drug Abuse at the National Institutes of Health as its funder, and the text read does not mention any author tie to a drug maker.3

Deeper analysis: the 2000 randomized trial of supraphysiologic doses

Pope, Kouri and Hudson reported the trial in Archives of General Psychiatry in 2000.8 Fifty-six normal men aged 20 to 50 years received testosterone cypionate for 6 weeks in doses rising to 600 mg per week and placebo for 6 weeks, 6 weeks apart, in a randomized, placebo-controlled, crossover design.8 Testosterone significantly increased YMRS manic scores (P = .002), manic scores on daily diaries (P = .003), visual analog ratings of liking the drug effect (P = .008) and aggressive responses (P = .03).8 Of 50 participants who received 600 mg per week, 42 (84%) had minimal psychiatric effects (maximum YMRS score below 10), 6 (12%) became mildly hypomanic (YMRS score 10 to 19) and 2 (4%) became markedly hypomanic (YMRS score 20 or more).8 The authors conclude that the effect “was not uniform across individuals; most showed little psychological change, whereas a few developed prominent effects”.8 The cited summary does not state the funder, any author tie to a sponsor, or the authors' own limitations.

Deeper analysis: the 2023 randomized comparison with intranasal gel

Rivero, Ory, Diaz, Thirumavalavan, Han, Reis and Ramasamy reported the trial in The Journal of Urology in 2023.7 Men aged 18 to 75 with two total testosterone levels below 350 ng/dL and hypogonadal symptoms were randomly assigned to intranasal testosterone gel 11 mg three times daily or intramuscular testosterone cypionate 200 mg every 2 weeks, and the primary outcome was the change in hematocrit after 4 months.7 Hematocrit increased from 42.7% to 46.6% in the injection group (P < .0001) while gel produced no significant change (P = .233).7 In the injection group estradiol also increased (mean change 22.9, P < .001) and 17-hydroxyprogesterone decreased (mean change -39.8, P < .0001), and PSA was stable in both groups.7 The trial was open-label, and 27 of the 81 randomized men did not complete treatment.7 The cited summary does not state the funder, any author tie to a sponsor, or the authors' own limitations.

7

Doses reported in studies and on labels

Table 7.1Doses reported in studies and on labels6 rows
SourceWhoDose reportedRoute
Depo-Testosterone label1Replacement in the hypogonadal male; the label states the suggested dosage varies with age, sex and diagnosis50 to 400 mg every two to four weeksIntramuscular, deep gluteal
Azmiro label2Males with hypogonadism; the label states the dose and schedule are individualized by age, diagnosis, response and adverse reactions50 mg to 400 mg every two to four weeks; prefilled syringe for 200 mg doses onlyIntramuscular, deep gluteal; prefilled syringe by a healthcare professional only
McFarland and colleagues, 2017611 transgender men; study supported by a Maine Medical Center grant50 to 100 mg weekly (median 75 mg)Subcutaneous
Pope and colleagues, 2000856 normal men aged 20 to 50Rising to 600 mg weekly for 6 weeksNot stated in the cited summary
Kouri and colleagues, 1996916 normal male volunteers150, 300 then 600 mg weekly, 2 weeks eachNot stated in the cited summary
Bi and colleagues, 20183Healthy men; the authors say the 250 and 500 mg/wk regimens resemble doses illegally used by athletes100, 250 or 500 mg weekly for 14 weeksRoute not stated in the text read (the authors discuss “The i.m. injection of TC” generally)

The app's typical dose range is 150 to 500 mg per week, while the labels state 50 to 400 mg every two to four weeks.1 The app's top of 500 mg per week falls in the range that Bi and colleagues say resembles doses illegally used by athletes, and Pope and colleagues describe doses rising to 600 mg per week as supraphysiologic.3,8 Nankin gave 200 mg intramuscular biweekly, Rivero 200 mg intramuscular every 2 weeks, Okano 100 mg intramuscular every 2 weeks and Choi 100 mg intramuscular weekly.5,7,11,10

What the labels list

The Depo-Testosterone label lists, among others, adverse reactions that have occurred with some androgens: gynecomastia, oligospermia at high dosages, acne, polycythemia, venous thromboembolism, myocardial infarction and stroke, and inflammation and pain at the site of intramuscular injection.1 It lists contraindications including carcinoma of the breast in males, known or suspected carcinoma of the prostate gland, women who are pregnant, and serious cardiac, hepatic or renal disease.1 On cardiovascular risk the Depo-Testosterone label states that “Some studies, but not all, have reported an increased risk of MACE in association with use of testosterone replacement therapy in men”.1 Both labels state that testosterone can increase blood pressure, which can increase cardiovascular risk over time, and both describe postmarketing reports of venous thromboembolic events including deep vein thrombosis and pulmonary embolism.1,2 The Azmiro label states that large doses of exogenous androgens may suppress spermatogenesis, that reduced fertility is observed in some men taking testosterone replacement therapy, that “The impact on fertility may be irreversible”, and that Azmiro may cause azoospermia.2 In Azmiro's Study 1, a randomized, single-dose, open-label study, 27 adult males with hypogonadism received a single 200 mg intramuscular dose or a comparator and were observed for 31 days, and the most common adverse reactions in those who received Azmiro were injection site erythema (26%) and injection site reaction (4%), all categorized as mild on a pre-defined scale; the number in each arm is not given.2

TRAVERSE, as the Azmiro label reports it (topical gel, not an injection)

The Azmiro label reports the TRAVERSE cardiovascular outcomes study of topical testosterone gel against placebo in 5198 hypogonadal men aged 45 to 80 years with a history of cardiovascular disease or multiple cardiovascular risk factors.2 The incidence of major adverse cardiovascular events was 7.0% (182 events) on gel and 7.3% (190 events) on placebo, hazard ratio 0.96 (95% CI 0.78 to 1.17), and approximately 61% of all patients discontinued gel or placebo.2 The label also reports, among others, for gel versus placebo, nonfatal arrhythmias warranting intervention (5.2% vs 3.3%), atrial fibrillation (3.5% vs 2.4%) and venous thromboembolism (1.7% vs 1.2%).2 The label does not state who funded TRAVERSE, and the study tested a gel, not testosterone cypionate.2

Findings in studies of testosterone cypionate

In the Pope trial, 600 mg per week raised manic scores and aggressive responses, with 6 of 50 men becoming mildly hypomanic and 2 of 50 markedly hypomanic.8 In Okano and colleagues, no serious adverse events were reported, and in McFarland and colleagues no adverse effects were encountered.11,6 In Rivero and colleagues hematocrit rose from 42.7% to 46.6% in the injection arm, and in Kouri and colleagues HDL cholesterol fell 21% and the total cholesterol/HDL-C ratio was significantly elevated.7,9 The Okano authors list as limitations “the absence of a sham control group and the use of a convenience sample recruited from a single specialized center”.11

The Milligram app lists total testosterone, free testosterone, estradiol, hematocrit, lipids and PSA as its markers for testosterone cypionate. The Depo-Testosterone label states that hemoglobin and hematocrit levels (to detect polycythemia) are checked periodically in patients receiving long-term androgen administration, and that serum cholesterol may increase during androgen therapy.1 Both labels state that blood pressure is monitored periodically.1,2 The Azmiro label also lists PSA monitoring, serum prolactin evaluation, periodic hematocrit monitoring and periodic lipid profile monitoring.2

Testosterone cypionate is a Schedule III controlled substance in the US: the Depo-Testosterone label states that the injection contains testosterone, “a Schedule III controlled substance in the Controlled Substances Act”.1 21 CFR 1308.13 lists testosterone (17β-hydroxyandrost-4-en-3-one) among Schedule III anabolic steroids, “including its salts, esters and ethers”.12 The World Anti-Doping Agency's 2026 Prohibited List places anabolic agents in S1, prohibited at all times in and out of competition, and anabolic androgenic steroids in S1.1 “When administered exogenously, including but not limited to”, followed by a list that includes testosterone.13

The Depo-Testosterone label states storage at 20° to 25°C (68° to 77°F) and protection from light.1 The Azmiro label states storage at 15°C to 25°C (59°F to 77°F) in the carton to protect contents from light.2

A 1980 comparison by Schulte-Beerbühl and Nieschlag of testosterone enanthate and testosterone cypionate has no summary text available, so its results are not reported here.14 The Azmiro label states that “The exposure-response relationship and time course of pharmacodynamic response for the safety and effectiveness of testosterone have not been fully characterized”.2 The pharmacokinetic samples are 11 men in Nankin5 and in McFarland6, 26 in the Azmiro label's study2 and 31 in Bi and colleagues,3 and McFarland and Bi and colleagues call their own samples small. The sources cited here are US labels, a US regulation, the WADA list and published studies, and labels from other countries were not among them.

What is the half-life of testosterone cypionate?

The US labels state that the half-life of testosterone cypionate when injected intramuscularly is approximately eight days.1,2 The Milligram app uses 192 hours (8 days). A 2018 population model of 31 healthy men given weekly doses of 100, 250 or 500 mg estimated a median half-life of total testosterone of 4.05 days.3

How long does testosterone cypionate take to peak?

The Azmiro label reports a median time to peak of baseline-corrected testosterone of 71.7 hours (range 24.0 to 191.0) after a single 200 mg intramuscular dose in 26 hypogonadal men.2 The Milligram app uses about 48 hours.

What does testosterone cypionate come in per mL?

The US Depo-Testosterone label lists strengths of 100 mg/mL and 200 mg/mL.1 The Azmiro label lists 200 mg/mL in a single-dose vial and a single-dose prefilled syringe.2

Is testosterone cypionate banned by WADA?

Testosterone is on the World Anti-Doping Agency's 2026 Prohibited List under S1.1, anabolic androgenic steroids, prohibited at all times when administered exogenously.13 The list text reads “and other substances with a similar chemical structure or similar biological effect(s) including their esters” and does not name cypionate.13

Is testosterone cypionate a controlled substance?

In the US, testosterone is a Schedule III controlled substance, and the Depo-Testosterone label carries the CIII designation.1

Is testosterone cypionate approved for subcutaneous injection?

The US labels for testosterone cypionate state intramuscular use.1,2 The app lists IM and SubQ routes. McFarland and colleagues measured weekly subcutaneous testosterone cypionate in 11 transgender men.6

Does testosterone cypionate raise hematocrit?

In a 2023 open-label randomized trial of testosterone-deficient men (81 randomized, 54 completed; 31 completed on injections), mean hematocrit increased from 42.7% to 46.6% (P < .0001) in men given 200 mg of intramuscular testosterone cypionate every 2 weeks for 4 months and did not change significantly with intranasal gel (P = .233).7

15

References

  1. Pharmacia & Upjohn Company LLC (Pfizer). Depo-Testosterone (testosterone cypionate) injection, USP CIII. DailyMed label, text revised October 2025; DailyMed record version 27, effective 10 November 2026. DailyMed label
  2. Azurity Pharmaceuticals, Inc. AZMIRO (testosterone cypionate) injection, for intramuscular use, CIII. DailyMed label, revised July 2025. DailyMed label
  3. Bi Y, Perry PJ, Ellerby M, Murry DJ. Population Pharmacokinetic/Pharmacodynamic Modeling of Depot Testosterone Cypionate in Healthy Male Subjects. CPT Pharmacometrics Syst Pharmacol 2018. PMC5915615
  4. Sun Pharmaceutical Industries, Inc. Testosterone Cypionate Injection, USP C-III. DailyMed label, revised June 2025. DailyMed label
  5. Nankin HR. Hormone kinetics after intramuscular testosterone cypionate. Fertil Steril 1987. PMID 3595893
  6. McFarland J, Craig W, Clarke NJ, Spratt DI. Serum Testosterone Concentrations Remain Stable Between Injections in Patients Receiving Subcutaneous Testosterone. J Endocr Soc 2017. PMC5686655
  7. Rivero MJ, et al. Comparison of Hematocrit Change in Testosterone-deficient Men Treated With Intranasal Testosterone Gel vs Intramuscular Testosterone Cypionate: A Randomized Clinical Trial. J Urol 2023. PMID 37126399
  8. Pope HG Jr, Kouri EM, Hudson JI. Effects of supraphysiologic doses of testosterone on mood and aggression in normal men: a randomized controlled trial. Arch Gen Psychiatry 2000. PMID 10665615
  9. Kouri EM, Pope HG, Oliva PS. Changes in lipoprotein-lipid levels in normal men following administration of increasing doses of testosterone cypionate. Clin J Sport Med 1996. PMID 8792045
  10. Choi EJ, et al. Comparison of Outcomes for Hypogonadal Men Treated with Intramuscular Testosterone Cypionate versus Subcutaneous Testosterone Enanthate. J Urol 2022. PMID 34694927
  11. Okano SHP, et al. Effect of 100 mg of testosterone cypionate in trans men with erythrocytosis: a randomized controlled pilot study. J Sex Med 2025. PMID 41052128
  12. US Drug Enforcement Administration. 21 CFR 1308.13, Schedule III. Electronic Code of Federal Regulations. 21 CFR 1308.13
  13. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. In force 1 January 2026. WADA Prohibited List 2026
  14. Schulte-Beerbühl M, Nieschlag E. Comparison of testosterone, dihydrotestosterone, luteinizing hormone, and follicle-stimulating hormone in serum after injection of testosterone enanthate of testosterone cypionate. Fertil Steril 1980. PMID 7353699